GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength
GSK PLC is expected to report Q3 results in line with estimates, with vaccine sales weakness offset by HIV treatments and Nucala. RBC forecasts Q3 revenue of £8.82B, slightly below consensus, and core EPS of 50.8p, matching expectations. The broker maintained its Sector Perform rating and 1,975p price target. GSK is set to report results on 28 October.
How this was made
The 30-second read
Why it matters
Guidance suggests a flat‑to‑slightly negative reaction unless vaccine sales improve.
Market read
First release of GSK's Q3 guidance ahead of earnings, shaping short‑term trader expectations.
What to watch
Potential cost‑saving initiatives and late‑stage pipeline developments not reflected in the guidance.
Background
RBC reiterates a Sector Perform rating with a 1,975p price target, noting vaccine headwinds offset by HIV and Nucala strength.
Ticker impact
RBC forecasts GSK's Q3 revenue and earnings ahead of its 28 Oct results, highlighting vaccine headwinds and HIV strength.
likely modest downside as investors price in vaccine drag and HIV offset
Guidance matches expectations; no surprise upside, but sector pressure on vaccines could trigger slight sell‑off.
Market effects
Vaccine segment may face broader pricing pressure, while HIV and respiratory drugs could buoy the pharma sector.
UK‑listed pharma stocks may see slight re‑rating ahead of earnings season.
GSK guidance influences global healthcare investors tracking vaccine and HIV pipelines.
Counterpoint
If vaccine pricing stabilises faster than expected, GSK could outperform peers.
Key entities
- analystRBC Capital Markets
Provides the Q3 guidance forecast and price target.
